



IDT Biologika Signs Pandemic Contingency Agreement with German Government

Dessau-Rosslau (Germany), May 3rd, 2022 – Today saw the signing of the pandemic agreements between the German government and five companies, including IDT Biologika, at the Paul-Ehrlich-Institut in Langen. Amongst other things, the framework agreement comprises the provision of vaccines in the event of a pandemic up until 2029.

Prior to this, IDT Biologika had taken part in the public tendering process for pandemic preparedness of the federal government and been awarded the contract. With the pandemic agreement IDT Biologika, following a qualification phase of a maximum of two years, grants the federal government access to production capacity for five years and is in a position to rapidly manufacture and supply at least 80 million doses of vaccine per year.

This is an important contribution to the supply of vaccines to people in Germany and other countries in the event of a continuation of the covid pandemic or the emergence of a new infectious disease, minimizing the risk of potential supply shortages.

“We welcome the initiative of the German government to place greater emphasis on pandemic contingency. With this, it is not only averting shortages in emergency situations and enabling citizens swift access to medical care, it is also acknowledging the capability of Germany as a pharmaceuticals location and reinforcing the innovativeness of the country. Being prepared for a pandemic requires the constant further development of processes, technologies, and expertise. And it is precisely here that IDT can make a substantial contribution and create something valuable for society,” says Dr. Jürgen Betzing, CEO IDT Biologika.

1,720 characters incl. blanks

About IDT Biologika

IDT Biologika is an innovative biotech company with a successful history dating back 100 years. Based on modern technologies and high levels of expertise, IDT supports customers in the development and manufacture of virus vaccines, gene and immune therapy products as well as biologics employed worldwide as protection against diseases. IDT Biologika employs approximately 1,650 people. German sites are the BioPharmaPark in Dessau-Rosslau and Magdeburg. In the US, the IDT Corporation has a manufacturing site for clinical test samples in Rockville, Maryland.

Website: www.idt-biologika.com



Contact IDT Biologika

Corinna Meisel

Corporate Communications Specialist

M +49 (0)173 9249671

corinna.meisel@idt-biologika.de

IDT Biologika GmbH

Am Pharmapark | D-06861 Dessau-Rosslau, Germany